- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01939899
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
October 7, 2019 updated by: Millennium Pharmaceuticals, Inc.
An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
The primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as measured by overall response rate (ORR) in adult participants with relapsed and/or refractory follicular lymphoma (FL).
Study Overview
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gent, Belgium
-
Leuven, Belgium
-
Wilrijk, Belgium
-
-
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
-
London, United Kingdom
-
Manchester, United Kingdom
-
Newcastle Upon Tyne, United Kingdom
-
Plymouth, United Kingdom
-
Southampton, United Kingdom
-
Sutton, United Kingdom
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
New York
-
New York, New York, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female participants 18 years or older.
- Participants must have a pathologically confirmed diagnosis of non-Hodgkin lymphoma (NHL) (for the lead-in dose-finding phase) and FL (for phase 2).
- Participants must have radiographically or clinically measurable disease.
- Participants must be relapsed and/or refractory after at least 1 prior therapy (excluding radiation) with documented progressive disease at the time of enrollment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to practice true abstinence.
- Male participants who agree to practice effective barrier contraception or agree to practice true abstinence.
- Voluntary written consent.
- Suitable venous access.
- Appropriate clinical laboratory values as defined in the protocol.
- Recovered from toxicities of prior anticancer therapy.
- If the trial proceeds to the second step on the basis of the tandem 2-step design, participants must be confirmed PSMB1 positive at the central laboratory before treatment.
Exclusion Criteria
- Peripheral neuropathy that is greater or equal to Grade 2 or Grade 1 with pain.
- Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.
- Autologous stem cell transplant within 6 months before Day 1 of Cycle 1, or prior allogeneic stem cell transplant at any time.
- Major surgery within 14 days before the first dose of study drug.
- Infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
- Comorbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the participants inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
- Evidence of current uncontrolled cardiovascular conditions including uncontrolled hypertension, severe uncontrolled ventricular arrhythmias, unstable angina, New York Heart Association (NYHA) Class III or IV cardiac disease, or myocardial infarction within the past 6 months.
- Diarrhea greater than (>) Grade 1 on the basis of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) categorization.
- Systemic antineoplastic (including glucocorticoids > the equivalent of 15 mg of prednisone daily), experimental, or radiation therapy within 21 days before the first dose of study drug.
- Prior treatment with rituximab or other unconjugated antibody treatment within 42 days (21 days if clear evidence of progressive disease or immediate treatment is mandated).
- Treatment with radioimmunoconjugates or toxin immunoconjugates within 12 weeks before the first dosing of study treatment.
- Systemic treatment with strong inhibitors of Cytochrome P450 1A2 (CYP1A2) or Cytochrome P450 3A (CYP3A), or strong CYP3A inducers within 14 days before the first dose of IXAZOMIB - Ongoing systemic therapy with corticosteroids.
- Central nervous system (CNS) involvement that is clinically uncontrolled or newly diagnosed in the last 4 months.
- Ongoing or active systemic viral infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus or known active hepatitis C virus.
- Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ.
- Platelet transfusions within 3 days before the 1st dose of study drug.
- Inability to swallow capsules, or inability or unwillingness to avoid taking anything by mouth except for water and prescribed medication for 2 hours before and 1 hour after dose of IXAZOMIB - Known allergy to boron or excipients in the formulation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IXAZOMIB
Ixazomib 4, 5.3 and 7 milligram (mg), orally, once on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days, for up to Cycle 29 or until disease progression or unacceptable toxicity at lead-in phase for participants with NHL.
After completion of lead-in phase, participants will continue into Phase 2. Participants in Phase 2 will receive Ixazomib at RP2D dose, orally, once weekly on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days , for up to Cycle 29 or until disease progression or unacceptable toxicity in Phase 2 for participants with RRFL.
|
Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Overall Response Rate (ORR)
Time Frame: Baseline up to Day 15 Cycle 29 (approximately up to Day 802) or until PD or the start of alternate therapies
|
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the investigator using the international Working Group criteria for participants CR: disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level.
PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
|
Baseline up to Day 15 Cycle 29 (approximately up to Day 802) or until PD or the start of alternate therapies
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lead-in Dose Finding Phase: Recommended Phase 2 Dose (RP2D)
Time Frame: Baseline up to Cycle 1 Day 28
|
Baseline up to Cycle 1 Day 28
|
|
Progression Free Survival (PFS)
Time Frame: Time from the date of first dose of study treatment to the date of first documented PD or death (approximately up to Day 802)
|
PFS is defined as the time from the date of first dose of study treatment to the date of first documented PD or death.
Participants without documentation of PD will be censored at the date of last response assessment that is SD or better.
Participants without response assessment will be censored at the date of first dose.
|
Time from the date of first dose of study treatment to the date of first documented PD or death (approximately up to Day 802)
|
Phase 2: Rate of Disease Control
Time Frame: Baseline or until occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (approximately up to Day 805)
|
Rate of disease control is defined as percentage of participants who achieved a SD or better for greater than or equal to (>=) 6 months.
|
Baseline or until occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (approximately up to Day 805)
|
Time to Response (TTR)
Time Frame: Time from the date of first dose of study treatment to the date of first documented PR or better response or death (approximately up to Day 802)
|
TTR is defined as the time from the date of first dose of study treatment to the date of the first documentation of a PR or better response in a participant who responded.
|
Time from the date of first dose of study treatment to the date of first documented PR or better response or death (approximately up to Day 802)
|
Duration of Response (DOR)
Time Frame: Time from the date of first documentation of a response to the date of first documented PD (approximately up to Day 802)
|
The DOR is defined as the time from the date of first documentation of a response to the date of first documented PD.
Responders without documentation of PD will be censored at the date of last response assessment.
DOR was categorized as CR+PR and CR.
|
Time from the date of first documentation of a response to the date of first documented PD (approximately up to Day 802)
|
Phase 2: Number of Participants With Response Rates in PSMB1 Positive and PSMB1 Negative
Time Frame: Baseline up to occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (approximately up to Day 802)
|
Baseline up to occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (approximately up to Day 802)
|
|
Number of Participants Experiencing 1 or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Baseline up to 30 days after last dose of study drug (approximately up to Day 832)
|
Baseline up to 30 days after last dose of study drug (approximately up to Day 832)
|
|
Lead-in Dose Finding Phase: Cmax: Maximum Observed Plasma Concentration for Ixazomib
Time Frame: Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
|
|
Lead-in Dose Finding Phase: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib
Time Frame: Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
|
|
Lead-in Dose Finding Phase: AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for Ixazomib
Time Frame: Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 31, 2013
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
March 23, 2017
Study Registration Dates
First Submitted
August 28, 2013
First Submitted That Met QC Criteria
September 6, 2013
First Posted (Estimate)
September 11, 2013
Study Record Updates
Last Update Posted (Actual)
October 29, 2019
Last Update Submitted That Met QC Criteria
October 7, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Follicular
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protease Inhibitors
- Ixazomib
Other Study ID Numbers
- C16017
- 2013-002302-32 (EudraCT Number)
- U1111-1164-7551 (Other Identifier: WHO)
- 166547 (Registry Identifier: HC-CTD)
- REec-2016-2137 (Registry Identifier: REec)
- 13/EM/0373 (Registry Identifier: NRES)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
Clinical Trials on IXAZOMIB
-
Mayo ClinicTakedaCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
SCRI Development Innovations, LLCMillennium Pharmaceuticals, Inc.CompletedMultiple MyelomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedLymphoma | Advanced Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors | Hematologic MalignanciesUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Non-hematologic MalignanciesUnited States, Canada
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
University of Wisconsin, MadisonMillennium Pharmaceuticals, Inc.Completed
-
Millennium Pharmaceuticals, Inc.Completed